News | PET Imaging | August 06, 2021

New production methods for cerium-134 advance technologies for imaging human disease and guiding treatment.

Cerium-134 can be targeted to provide an imaging analogue for two different therapy isotopes, actinium-225 and thorium-227. This helps scientists understand these therapy isotopes and develop new treatments. Image courtesy of Donald Montoya, Los Alamos National Laboratory

Cerium-134 can be targeted to provide an imaging analogue for two different therapy isotopes, actinium-225 and thorium-227. This helps scientists understand these therapy isotopes and develop new treatments. Image courtesy of Donald Montoya, Los Alamos National Laboratory


August 6, 2021 — A multidisciplinary team has demonstrated the production, purification, and potential application of cerium-134. This isotope decays into lanthanum-134, an isotope useful for positron emission tomography (PET) imaging. PET imaging uses radioactive substances to visualize and measure processes in the body. It is an essential tool in diagnosing disease and monitoring treatment. The team demonstrated the use of cerium-134 for PET imaging in mice. The results show that cerium-134, through its lanthanum-134 decay product, could serve as a diagnostic partner for medical treatments based on actinium-225 or thorium-227.

Increasing the availability of cerium-134 for imaging could benefit the medical use of therapeutic radioactive isotopes. These isotopes emit alpha particles that target cancer and other diseases. Cerium-134 is chemically similar to actinium-225 and thorium-227. This means cerium-134 can be attached to the same targeting systems as the therapeutic isotopes. Using the same targeting systems means that cerium-134 diagnostics and actinium-225 and thorium-227 treatments will behave in similar ways in the body. This allows scientists to use cerium-134 to view and monitor actinium-225 and thorium-227 as they work. The result is more information for medical researchers and clinicians treating disease.

Developing targeted medical interventions that use radioactive isotopes to treat disease could transform how science treats disease. This approach involves selectively delivering an alpha-emitting radioisotope like actinium-225 and thorium-227 to diseased cells such as tumors. The radioactive decay kills the diseased cell while sparing the surrounding healthy tissue. Widespread implementation of this approach would be easier if medical practitioners had more tools to non-invasively and accurately track the radioactive medication in the body. One such tool is PET imaging with cerium-134. Unfortunately, actinium-225, thorium-227, and many other alpha-emitting radioisotopes are incompatible with PET imaging. The team demonstrated in mice that PET imaging cerium-134, through its lanthanum-134 decay product, can track actinium-225 and thorium-227. Greater availability of cerium-134 therefore opens the door to the development of additional targeted cancer therapies.

For more information: www.isotopes.gov


Related Content

News | Radiopharmaceuticals and Tracers

May 30, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 30, 2023
arrow
News | Breast Imaging

May 25, 2023 — GE HealthCare, a leader in breast cancer care technology and diagnostics, has today announced that NCCN ...

Time May 25, 2023
arrow
News | ASTRO

May 23, 2023 — More than 9 in 10 radiation oncologists report that their practices face clinical staff shortages ...

Time May 23, 2023
arrow
News | Radiation Oncology

May 22, 2023 — Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest ...

Time May 22, 2023
arrow
News | PET Imaging

May 22, 2023 — New research finds that the brains of otherwise healthy military personnel who are exposed to explosions ...

Time May 22, 2023
arrow
News | Radiation Oncology

May 16, 2023 — The American Society for Radiation Oncology (ASTRO) today expressed its strong support for President ...

Time May 16, 2023
arrow
News | Contrast Media

May 16, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a ...

Time May 16, 2023
arrow
News | Contrast Media

May 15, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced that ...

Time May 15, 2023
arrow
News | PET Imaging

May 12, 2023 — A newly published meta-analysis indicates that amino acid PET can accurately differentiate recurrent or ...

Time May 12, 2023
arrow
News | Prostate Cancer

May 2, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 02, 2023
arrow
Subscribe Now